← back to search

Michael J. Robertson

Indiana University Health · US
Area of research
Immunology · Pathology and Forensic Medicine
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Immune Cell Function and Interaction, Hematopoietic Stem Cell Transplantation, and Receptor Mechanisms and Signaling.
h-index
65
citations
16,463
works
330
NIH funding
primary concept
Medicine
email

Recent publications

A µ-opioid receptor superagonist analgesic with minimal adverse effects
Nature 2026cited by 4position: middledoi
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma
Blood 2026cited by 1position: middledoi
A µ-opioid receptor superagonist analgesic with minimal adverse effects.
2026cited by 1position: contributordoi
Snapshots of the dynamic basis of NTSR1 G protein subtype promiscuity.
2026cited by 1position: contributordoi
Author Correction: A µ-opioid receptor superagonist analgesic with minimal adverse effects.
2026cited by 0position: contributordoi
MIC: A deep learning tool for assigning ions and waters in cryo-EM and crystal structures
Nature Communications 2025cited by 8position: lastdoi
Non-Equilibrium Snapshots of Ligand Efficacy at the μ-Opioid Receptor
2025cited by 4position: contributordoi
MIC: A deep learning tool for assigning ions and waters in cryo-EM and crystal structures.
2025cited by 3position: contributordoi
Therapy duration and improvement of ventricular function in <i>de novo</i> heart failure: the Heart Failure Optimization study
European Heart Journal 2024cited by 55position: middledoi
Allosteric modulation and G-protein selectivity of the Ca&lt;sup&gt;2+&lt;/sup&gt;-sensing receptor.
2024cited by 51position: contributordoi
Metric Ion Classification (MIC): A deep learning tool for assigning ions and waters in cryo-EM and x-ray crystallography structures
2024cited by 3position: contributordoi
A Putative Binding Model of Nitazene Derivatives at the <i>μ</i> -Opioid Receptor
2024cited by 0position: contributordoi
Insights into distinct signaling profiles of the µOR activated by diverse agonists.
2023cited by 115position: contributordoi
Structure-based design of bitopic ligands for the µ-opioid receptor.
2023cited by 106position: contributordoi
Structural basis for activation of CB1 by an endocannabinoid analog.
2023cited by 46position: contributordoi
Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity
Nature 2022cited by 248position: middledoi
Bespoke library docking for 5-HT<sub>2A</sub> receptor agonists with antidepressant activity.
2022cited by 190position: contributordoi
Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD
Neuron 2022cited by 151position: middledoi
The tethered peptide activation mechanism of adhesion GPCRs.
2022cited by 125position: contributordoi
Structure determination of inactive-state GPCRs with a universal nanobody.
2022cited by 108position: contributordoi
Structure and mechanism of the SGLT family of glucose transporters.
2022cited by 90position: contributordoi
Structural basis for recognition of N-formyl peptides as pathogen-associated molecular patterns.
2022cited by 43position: contributordoi
The oxytocin signaling complex reveals a molecular switch for cation dependence.
2022cited by 41position: contributordoi
Plasticity in ligand recognition at somatostatin receptors.
2022cited by 39position: contributordoi
Development of OPLS-AA/M Parameters for Simulations of G Protein-Coupled Receptors and Other Membrane Proteins.
2022cited by 11position: contributordoi
Author Correction: Plasticity in ligand recognition at somatostatin receptors.
2022cited by 0position: contributordoi
Structure and mechanism of the SGLT family of glucose transporters
Nature 2021cited by 142position: middledoi
G-protein activation by a metabotropic glutamate receptor.
2021cited by 129position: contributordoi
Asymmetric activation of the calcium-sensing receptor homodimer.
2021cited by 104position: contributordoi
Isolating Conformers to Assess Dynamics of Peptidic Catalysts Using Computationally Designed Macrocyclic Peptides.
2021cited by 16position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Georgios Skiniotis · Stanford Medicine32 papers (2019–2026) · 31 papers (2019–2026) · 24 papers (2019–2026)Brian K. Kobilka · Stanford University6 papers (2019–2023)Justin Meyerowitz · Revolution Medicines (United States)6 papers (2021–2022)Makaía M. Papasergi-Scott · Stanford University6 papers (2020–2025)Bryan L. Roth · University of North Carolina at Chapel Hill6 papers (2020–2023)Jesper Mosolff Mathiesen · University of Copenhagen5 papers (2020–2024) · 4 papers (2021–2023)Tao Che · Saint Louis University4 papers (2022–2023)Susruta Majumdar · Laboratory of Molecular Genetics4 papers (2021–2025)Qianhui Qu · Fudan University4 papers (2019–2023)Ron O. Dror · Stanford Medicine4 papers (2021–2023) · 4 papers (2021–2023)Yang Gao · Nanfang Hospital4 papers (2021–2024)Catherine Diefenbach · NYU Langone Health4 papers (2015–2026)Brad S. Kahl · New York University4 papers (2015–2026)Ximena Barros-Álvarez · Stanford University3 papers (2021–2022)Lei Shi · National Institute on Drug Abuse3 papers (2024–2026)Jonathon B. Cohen · Emory University3 papers (2015–2020)